NCT02547792 is a Phase 1 clinical trial of VXA-BYW.10 (Low Dose) Oral Vaccine in Seasonal Influenza B, sponsored by Vaxart.

Who is sponsoring NCT02547792?

NCT02547792 is sponsored by Vaxart.

What drugs are being tested in NCT02547792?

Interventions in NCT02547792: VXA-BYW.10 (Low Dose) Oral Vaccine, VXA-BYW.10 (High Dose) Oral Vaccine, Placebo Tablets.

What condition does NCT02547792 study?

NCT02547792 studies Seasonal Influenza B.

Is NCT02547792 still recruiting?

NCT02547792 is currently completed. Last updated 31 May 2018.

Last reviewed 2018-05-31 · How we verify

NCT02547792

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Completed Phase 1 Last updated 31 May 2018

What this trial tests

Phase 1 trial testing VXA-BYW.10 (Low Dose) Oral Vaccine in Seasonal Influenza B in 54 participants. Completed in 21 November 2016.

Timeline

20 October 2015

Primary endpoint
21 November 2016

21 November 2016

Quick facts

Lead sponsor	Vaxart
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	54
Start date	20 October 2015
Primary completion	21 November 2016
Estimated completion	21 November 2016
Sites	1 location across New Zealand

Drugs / interventions tested

VXA-BYW.10 (Low Dose) Oral Vaccine — full drug profile →
VXA-BYW.10 (High Dose) Oral Vaccine — full drug profile →
Placebo Tablets — full drug profile →

Conditions studied

Seasonal Influenza B — all drugs for Seasonal Influenza B →

Sponsor

Vaxart — full company profile →

Who can join

Adults 18 to 49, any sex, with Seasonal Influenza B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1, single-center, placeb-controlled, double-blind study. The purpose of this study is to determine the safety and immunogenicity of an oral vaccine tablet to prevent seasonal influenza B tested at two dose levels (low and high dose). The study will enroll 27 subjects in the low dose cohorts (3 sentinel open label subjects followed by 24 subjects (randomized 2:1 to vaccine vs placebo, respectively). Subsequently, 27 subjects will be enrolled in the high dose cohort in a similar manner as to the low dose cohort. Safety and immunogenicity will be evaluated at Day 28. Long term safety follow-up will be evaluated through 1 year post vaccination.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Noninvasive vaccination against infectious diseases.
Zheng Z, Diaz-Arévalo D, Guan H, Zeng M. · · 2018 · cited 46× · PMID 29624470 · DOI 10.1080/21645515.2018.1461296
Ebola virus disease candidate vaccines under evaluation in clinical trials.
Martins KA, Jahrling PB, Bavari S, Kuhn JH. · · 2016 · cited 37× · PMID 27160784 · DOI 10.1080/14760584.2016.1187566
Blades and barriers: Oral vaccines for conquering cancers and warding off infectious diseases.
Yang K, Liu J, Zhao Y, Xu H, et al · · 2025 · PMID 40893667 · DOI 10.1016/j.apsb.2025.05.038

Verify or expand the search:

Other Vaxart trials

Trials by the same sponsor.

NCT06944717 — A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years · Phase 1 · active not recruiting
NCT07254728 — A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing I · Phase 1 · completed
NCT05626803 — A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers · Phase 2 · completed
NCT05213728 — A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-v · Phase 1 · completed
NCT05212168 — Norovirus Challenge Study · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02547792 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vaxart
Last refreshed: 31 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02547792.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing